<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431794</url>
  </required_header>
  <id_info>
    <org_study_id>J1130</org_study_id>
    <secondary_id>NA_00047491</secondary_id>
    <nct_id>NCT01431794</nct_id>
  </id_info>
  <brief_title>Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Viragh Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine
      and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib). The objective is to
      assess tolerability and the resection rate of patients with borderline resectable pancreatic
      adenocarcinoma who use this treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose treating 6-12 patients during the phase 1 portion and 40 patients
      in the phase 2 stage.

      Phase 1 Stage:

      Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 in
      combination with escalating doses (400mg, or 600mg, or 800mg) of LDE-225. After completion of
      neoadjuvant therapy, the subjects will receive combined chemotherapy and radiation. Then
      subjects who are eligible for resection will go ahead with surgery. Following resection,
      subjects will complete two additional cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125
      mg/m2 in combination with LDE-225.

      Phase 2 Stage: In the Phase 2 stage the patients will be randomized to receive gemcitabine
      and nab-paclitaxel with or without the hedgehog inhibitor LDE225:

        1. Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m on days 1, 8
           and 15 in combination with LDE-225 at the recommended phase 2 dose.

        2. Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m on days 1, 8
           and 15.

      After completion of neoadjuvant therapy, the subjects will receive combined chemotherapy and
      radiation. Then subjects who are eligible for resection will go ahead with surgery. Following
      resection, subjects will complete two additional cycles of the pre-surgical therapy.

      Several correlative laboratory studies will be conducted during the course of this study.
      They were designed around the goals of providing us with a better understanding of how the
      stroma-tumor interaction and the intra-tumoral drug levels of gemcitabine are affected with
      the use of LDE-225. Two additional biopsies are required to participate in this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to cease in manufacturing of study drug.
  </why_stopped>
  <start_date type="Actual">December 27, 2011</start_date>
  <completion_date type="Actual">November 5, 2018</completion_date>
  <primary_completion_date type="Actual">November 5, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who tolerated the maximal dose of LDE-225 in combination with gemcitabine, nab-paclitaxel as neoadjuvant therapy in patients with borderline resectable pancreatic adenocarcinoma (PDA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with borderline resectable pancreatic adenocarcinoma (PDA) who undergo resection after therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Number of months alive from cycle 1, Day 1 until 5 years post-intervention or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who experienced complete response (CR) or partial response (PR), as defined by RECIST v1.0; where CR is a disappearance of all target lesions and PR is â‰¥30% reduction of target lesions.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II-Arm A:Gem,nab-paclitaxel,LDE225</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II-Arm B:Gem,nab-paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225-600mg</intervention_name>
    <description>Phase I: oral LDE225 (Sonidegib), 600mg daily.
Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.</description>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-600mg</arm_group_label>
    <arm_group_label>Phase II-Arm A:Gem,nab-paclitaxel,LDE225</arm_group_label>
    <other_name>Sonidegib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.</description>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-400mg</arm_group_label>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-600mg</arm_group_label>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-800mg</arm_group_label>
    <arm_group_label>Phase II-Arm A:Gem,nab-paclitaxel,LDE225</arm_group_label>
    <arm_group_label>Phase II-Arm B:Gem,nab-paclitaxel</arm_group_label>
    <other_name>gem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.</description>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-400mg</arm_group_label>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-600mg</arm_group_label>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-800mg</arm_group_label>
    <arm_group_label>Phase II-Arm A:Gem,nab-paclitaxel,LDE225</arm_group_label>
    <arm_group_label>Phase II-Arm B:Gem,nab-paclitaxel</arm_group_label>
    <other_name>abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225-400mg</intervention_name>
    <description>Phase I: oral LDE225 (Sonidegib), 400mg daily.</description>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-400mg</arm_group_label>
    <arm_group_label>Phase II-Arm A:Gem,nab-paclitaxel,LDE225</arm_group_label>
    <other_name>Sonidegib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225-800mg</intervention_name>
    <description>Phase I: oral LDE225 (Sonidegib), 800mg daily.</description>
    <arm_group_label>Phase I-Gem,nab-paclitaxel,LDE225-800mg</arm_group_label>
    <arm_group_label>Phase II-Arm A:Gem,nab-paclitaxel,LDE225</arm_group_label>
    <other_name>Sonidegib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas.

          -  Must have borderline resectable pancreatic adenocarcinoma

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension

          -  No previous radiotherapy, surgery, chemotherapy or investigational drug therapy.

          -  Age &gt;18 years

          -  Life expectancy of greater than 1 month.

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1

          -  Adequate organ and marrow function

          -  Asymptomatic for jaundice and ascites. Pain symptoms should be stable.

          -  Negative serum pregnancy test

          -  Sexually active males should agree to use a barrier form of contraception, even if
             they have had a vasectomy, during the study and for 6 months after stopping LDE225.
             Males should not donate sperm during treatment, and for up to six months after last
             dose. Sexually active females of child bearing potential agree to using highly
             effective contraception during study and for 20 months after final dose of LDE225.

          -  Agree not to donate blood products for 12 months after stopping LDE225.

          -  Willing to have two biopsies while on treatment for correlative studies.

        Exclusion Criteria:

          -  Patients who have had previous radiotherapy, surgical resection, chemotherapy or
             investigational drug therapy for pancreatic adenocarcinoma.

          -  Patient has known metastatic disease.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to LDE225 or other agents used in the study.

          -  Patients taking medications with narrow therapeutic indices that are metabolized by
             cytochrome P450 (CYP450), including warfarin sodium (CoumadinÂ®)

          -  Uncontrolled illness including, but not limited to, ongoing or active infection
             requiring IV antibiotics, symptomatic congestive heart failure not controlled with
             medication, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Pregnant women are excluded

          -  Patient has undergone a major surgery, other than diagnostic surgery within four weeks
             prior to starting treatment on this study.

          -  Patients who are receiving treatment with medications known to be moderate and strong
             inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have
             narrow therapeutic index, and that cannot be discontinued before starting treatment
             with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at
             least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting
             treatment with LDE225.

          -  Patients with neuromuscular disorders.

          -  Patients with impaired cardiac function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana De Jesus-Acosta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center JHMI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <results_first_submitted>March 1, 2019</results_first_submitted>
  <results_first_submitted_qc>June 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2019</results_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic ductal adenocarcinoma (PDA)Neoplasms</keyword>
  <keyword>LDE225</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>abraxane</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>cytotoxic</keyword>
  <keyword>hedgehog inhibitor</keyword>
  <keyword>stromal cells</keyword>
  <keyword>resectable PDA</keyword>
  <keyword>Pancreatic Diseases</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Sonidegib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT01431794/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10 subjects were screen failures. All of 13 subjects were enrolled into the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. Other Arm/group did not enroll any subjects due to early termination of the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Gem, Nab-paclitaxel, and LDE225-600mg</title>
          <description>Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Phase I: Gem, Nab-paclitaxel, and LDE225-400mg</title>
          <description>Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.</description>
        </group>
        <group group_id="P3">
          <title>Phase I: Gem, Nab-paclitaxel, and LDE225-800mg</title>
          <description>Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.</description>
        </group>
        <group group_id="P4">
          <title>Phase II: Arm A - Gem, Nab-paclitaxel, and LDE 225</title>
          <description>Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.</description>
        </group>
        <group group_id="P5">
          <title>Phase II: Arm B - Gemcitabine and Nab-paclitaxel</title>
          <description>Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0">not started due to early study's termination</participants>
                <participants group_id="P3" count="0">not started due to early study's termination</participants>
                <participants group_id="P4" count="0">not started due to early study's termination</participants>
                <participants group_id="P5" count="0">not started due to early study's termination</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0">not started due to early study's termination</participants>
                <participants group_id="P3" count="0">not started due to early study's termination</participants>
                <participants group_id="P4" count="0">not started due to early study's termination</participants>
                <participants group_id="P5" count="0">not started due to early study's termination</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants were enrolled in Phase 1, gem, nab-paclitaxel, and LDE225-600mg arm only. Other arms did not have any participants due to the study's early termination.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I, Gem, Nab-paclitaxel, and LDE225-600mg</title>
          <description>Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Phase I, Gem, Nab-paclitaxel, and LDE225-400mg</title>
          <description>Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 400 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Phase I, Gem, Nab-paclitaxel, and LDE225-800mg</title>
          <description>Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 800 mg daily</description>
        </group>
        <group group_id="B4">
          <title>Phase II, Arm A: Gem, Nab-paclitaxel, and LDE 225</title>
          <description>Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose from Phase I. Cycles repeated every 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Phase II, Arm B: Gemcitabine and Nab-paclitaxel</title>
          <description>Phase II:
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.62" spread="9.32"/>
                    <measurement group_id="B6" value="61.62" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225</title>
        <description>Number of participants who tolerated the maximal dose of LDE-225 in combination with gemcitabine, nab-paclitaxel as neoadjuvant therapy in patients with borderline resectable pancreatic adenocarcinoma (PDA).</description>
        <time_frame>5 years</time_frame>
        <population>This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-600mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-400mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.</description>
          </group>
          <group group_id="O3">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-800mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225</title>
          <description>Number of participants who tolerated the maximal dose of LDE-225 in combination with gemcitabine, nab-paclitaxel as neoadjuvant therapy in patients with borderline resectable pancreatic adenocarcinoma (PDA).</description>
          <population>This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II - Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA</title>
        <description>Number of participants with borderline resectable pancreatic adenocarcinoma (PDA) who undergo resection after therapy</description>
        <time_frame>5 years</time_frame>
        <population>No data was collected to assess this outcome measure as the study was terminated before Phase II.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II-Arm A:Gem,Nab-paclitaxel,LDE225</title>
            <description>Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
LDE225-600mg: Phase I: oral LDE225 (Sonidegib), 600mg daily.
Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.
Gemcitabine: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
nab-paclitaxel: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
LDE225-400mg: Phase I: oral LDE225 (Sonidegib), 400mg daily.
LDE225-800mg: Phase I: oral LDE225 (Sonidegib), 800mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Phase II-Arm B:Gem,Nab-paclitaxel</title>
            <description>Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
Gemcitabine: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
nab-paclitaxel: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II - Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA</title>
          <description>Number of participants with borderline resectable pancreatic adenocarcinoma (PDA) who undergo resection after therapy</description>
          <population>No data was collected to assess this outcome measure as the study was terminated before Phase II.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of months alive from cycle 1, Day 1 until 5 years post-intervention or death, whichever comes first.</description>
        <time_frame>5 years</time_frame>
        <population>This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-600mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-400mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.</description>
          </group>
          <group group_id="O3">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-800mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of months alive from cycle 1, Day 1 until 5 years post-intervention or death, whichever comes first.</description>
          <population>This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="3.7" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response</title>
        <description>Number of participants who experienced complete response (CR) or partial response (PR), as defined by RECIST v1.0; where CR is a disappearance of all target lesions and PR is â‰¥30% reduction of target lesions.</description>
        <time_frame>5 years</time_frame>
        <population>This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-600mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-400mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.</description>
          </group>
          <group group_id="O3">
            <title>Phase I: Gem, Nab-paclitaxel, and LDE225-800mg</title>
            <description>Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response</title>
          <description>Number of participants who experienced complete response (CR) or partial response (PR), as defined by RECIST v1.0; where CR is a disappearance of all target lesions and PR is â‰¥30% reduction of target lesions.</description>
          <population>This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 3 years</time_frame>
      <desc>Only for eligible participants. There were no participants enrolled in Phase I: gem, nab-paclitaxel, and LDE225-400mg, Phase I: gem, nab-paclitaxel, and LDE225-800mg, Phase II Arm A, and Phase II Arm B because the study was terminated early</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I, Gem, Nab-paclitaxel, and LDE225-600mg</title>
          <description>Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle with oral LDE225, 600mg.</description>
        </group>
        <group group_id="E2">
          <title>Phase I, Gem, Nab-paclitaxel, and LDE225-400mg</title>
          <description>Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle with oral LDE225, 400mg.</description>
        </group>
        <group group_id="E3">
          <title>Phase I, Gem, Nab-paclitaxel, and LDE225-800mg</title>
          <description>Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2o n days 1, 8, and 15 every 28 days cycle with oral LDE225, 800mg.</description>
        </group>
        <group group_id="E4">
          <title>Phase II, Arm A: Gem, Nab-paclitaxel, and LDE 225</title>
          <description>Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase I dose. Cycles repeated every 28 days.</description>
        </group>
        <group group_id="E5">
          <title>Phase II, Arm B: Gemcitabine and Nab-paclitaxel</title>
          <description>Phase II:
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>elevated creatine kinase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>fever and tachydysrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdomina pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>toxic mega-colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea, vomitting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>spesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>WBC decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>count of white blood cells</description>
                <counts group_id="E1" events="68" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <description>hemoglobin count decreased and anemia</description>
                <counts group_id="E1" events="60" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Albumin decreased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lymphocytes decreased</sub_title>
                <counts group_id="E1" events="51" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neutrophiles decreased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Platelets decreased</sub_title>
                <description>platelets count decreased</description>
                <counts group_id="E1" events="23" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdomin pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <description>alanine aminotransferase level increased</description>
                <counts group_id="E1" events="30" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <description>Aspartate aminotransferase level increased</description>
                <counts group_id="E1" events="34" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>sodium decreased</sub_title>
                <description>sodium ion decreased</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Glucose increased</sub_title>
                <description>blood glucose level increased</description>
                <counts group_id="E1" events="52" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>alkaline phosphatase level increased</description>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Calcium decreased</sub_title>
                <description>calcium ion in blood decreased</description>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ana De Jesus-Acosta</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>443-287-0411</phone>
      <email>adejesu1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

